However, Fiala et al. reported that high pre-treatment levels of CEA and/or Cyfra21-1 were associated with poor outcome for advanced NSCLC patients treated with erlotinib [22]. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.